CF
BDTX icon

Cantor Fitzgerald’s Black Diamond Therapeutics BDTX Stock Holding History

Cantor Fitzgerald’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-105,039
Closed -$489K – 228
2024
Q2 		$489K Buy
+105,039
New +$564K 0.1% 110

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Cantor Fitzgerald's BDTX Position: Q3 2024 in Review

Cantor Fitzgerald sold out of Black Diamond Therapeutics (BDTX) in Q3 2024, closing a stake of 105,039 shares — an estimated $489K sold.

Cantor Fitzgerald first reported a position in BDTX in Q2 2024 and held it in 1 quarter. The position peaked at $489K in Q2 2024. 96 funds tracked by Wall St. Rank hold BDTX as of Q3 2024.

  • Cantor Fitzgerald reported no remaining Black Diamond Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cantor Fitzgerald sold 105,039 Black Diamond Therapeutics shares in Q3 2024, an estimated $489K.
  • Cantor Fitzgerald first reported a position in Black Diamond Therapeutics in Q2 2024 and held it in 1 quarter.
  • Cantor Fitzgerald's Black Diamond Therapeutics position peaked at $489K in Q2 2024.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2024.

Based on Cantor Fitzgerald's 13F filing for Q3 2024, filed 14 Nov 2024.